OCV-C02
/ Otsuka
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 17, 2017
Phase 1 trial of OCV-C02, a peptide vaccine for metastatic colorectal cancer patients refractory to all standard chemotherapies.
(ASCO-GI 2017)
- P1; "OCV-C02 at 0.3 to 6 mg/body exhibited a safe and well tolerated profile, and showed immunological responses in mCRC pts refractory to all standard chemotherapies."
Clinical • P1 data • Biosimilar • Colorectal Cancer • Gastrointestinal Cancer • Immunology • Oncology
1 to 1
Of
1
Go to page
1